<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996307</url>
  </required_header>
  <id_info>
    <org_study_id>V112_06</org_study_id>
    <nct_id>NCT00996307</nct_id>
  </id_info>
  <brief_title>Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to &lt;36 Months</brief_title>
  <official_title>Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to &lt;36 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of different combinations of A/H1N1
      2009 (swine flu) vaccine in healthy young children
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Responses After the First and Second Vaccinations</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</measure>
    <time_frame>Day 1 to 7</time_frame>
    <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after first vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</measure>
    <time_frame>Day 22 to 28</time_frame>
    <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after second vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Measurement by Geometric Mean Titers (GMT)</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <description>Immunogenicity was measured in terms of the GMT at 21 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</measure>
    <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
    <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</measure>
    <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
    <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response Based on Baseline Seropositivity</measure>
    <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
    <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</measure>
    <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
    <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10 Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline (Day 1 (pre-vaccination)) as compared to those who are seronegative (HI titer &lt; 1:10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Persistence by Geometric Mean Titers (GMT)</measure>
    <time_frame>6 months (Day 202) and 12 months (Day 387) after second vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric Mean Titers (GMT at 6 months (Day 202)and 12 months (Day 387) after second vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(0)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15_(0)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>7.5_(0)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>15_(0)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>7.5_(50)MF59</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 6 to 35 months of age in good health as determined by medical history,
             physical assessment and clinical judgement of the investigator and without influenza
             within the past 6 months

        Exclusion Criteria:

          -  History of serious disease.

          -  History of serious reaction following administration of vaccine or hypersensitivity to
             vaccine components.

          -  Known or suspected impairment/alteration of immune function.

          -  Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week
             before or after each study vaccination

        For additional entry criteria, please refer to protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delegacion Tlalpan</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>April 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2011</results_first_posted>
  <disposition_first_submitted>October 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 15, 2010</disposition_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Swine Flu</keyword>
  <keyword>Flu</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Children</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>A/H1N1 2009 Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 29 sites in USA and Mexico. Five subjects received wrong vaccination according to the randomization and were excluded from PPS but were included in the safety set.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial. The data entered is for the overall study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="165"/>
            <count group_id="B5" value="654"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>6 to &lt;36 Months age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.2" spread="7.9"/>
                    <measurement group_id="B2" value="21.6" spread="8.8"/>
                    <measurement group_id="B3" value="21.1" spread="8.4"/>
                    <measurement group_id="B4" value="21.3" spread="8.9"/>
                    <measurement group_id="B5" value="21.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Responses After the First and Second Vaccinations</title>
        <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.</description>
        <time_frame>21 days after each vaccination</time_frame>
        <population>The analysis was done on the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses After the First and Second Vaccinations</title>
          <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.</description>
          <population>The analysis was done on the per-protocol set (PPS).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI titer ≥1:40 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12" upper_limit="26"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O3" value="15" lower_limit="9" upper_limit="23"/>
                    <measurement group_id="O4" value="19" lower_limit="13" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="71" upper_limit="86"/>
                    <measurement group_id="O2" value="37" lower_limit="29" upper_limit="46"/>
                    <measurement group_id="O3" value="86" lower_limit="78" upper_limit="91"/>
                    <measurement group_id="O4" value="50" lower_limit="41" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="65" upper_limit="81"/>
                    <measurement group_id="O2" value="32" lower_limit="24" upper_limit="41"/>
                    <measurement group_id="O3" value="80" lower_limit="72" upper_limit="87"/>
                    <measurement group_id="O4" value="44" lower_limit="35" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="70" lower_limit="61" upper_limit="78"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="81" lower_limit="74" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="68" lower_limit="59" upper_limit="76"/>
                    <measurement group_id="O3" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="76" lower_limit="68" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 202;N=45,38,46,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="85" upper_limit="99"/>
                    <measurement group_id="O2" value="50" lower_limit="33" upper_limit="67"/>
                    <measurement group_id="O3" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O4" value="55" lower_limit="38" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion Day 202;N=45,38,46,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="76" upper_limit="96"/>
                    <measurement group_id="O2" value="50" lower_limit="33" upper_limit="67"/>
                    <measurement group_id="O3" value="91" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O4" value="39" lower_limit="24" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 387;N=46,37,38,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="71" upper_limit="94"/>
                    <measurement group_id="O2" value="27" lower_limit="14" upper_limit="44"/>
                    <measurement group_id="O3" value="84" lower_limit="69" upper_limit="94"/>
                    <measurement group_id="O4" value="36" lower_limit="21" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion Day 387;N=45,38,46,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="61" upper_limit="87"/>
                    <measurement group_id="O2" value="22" lower_limit="10" upper_limit="38"/>
                    <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                    <measurement group_id="O4" value="25" lower_limit="12" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Measurement by Geometric Mean Titers (GMT)</title>
        <description>Immunogenicity was measured in terms of the GMT at 21 days after each vaccination.</description>
        <time_frame>21 days after each vaccination</time_frame>
        <population>The analysis was done on the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Measurement by Geometric Mean Titers (GMT)</title>
          <description>Immunogenicity was measured in terms of the GMT at 21 days after each vaccination.</description>
          <population>The analysis was done on the Full Analysis Set (FAS).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.94" upper_limit="14"/>
                    <measurement group_id="O2" value="7.27" lower_limit="5.5" upper_limit="9.6"/>
                    <measurement group_id="O3" value="9.29" lower_limit="7.06" upper_limit="12"/>
                    <measurement group_id="O4" value="11" lower_limit="8.22" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="56" upper_limit="123"/>
                    <measurement group_id="O2" value="20" lower_limit="14" upper_limit="31"/>
                    <measurement group_id="O3" value="92" lower_limit="62" upper_limit="136"/>
                    <measurement group_id="O4" value="37" lower_limit="25" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="642" lower_limit="468" upper_limit="879"/>
                    <measurement group_id="O2" value="80" lower_limit="58" upper_limit="110"/>
                    <measurement group_id="O3" value="626" lower_limit="457" upper_limit="858"/>
                    <measurement group_id="O4" value="151" lower_limit="110" upper_limit="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided confidence intervals (CIs) were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.55</ci_lower_limit>
            <ci_upper_limit>6.46</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 22</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 22</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>7.19</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 22</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 22</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>8.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.52</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 43</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.94</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 43</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.36</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 43</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two-sided CIs were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667 (based on CBER guidance against the licensed comparator).</non_inferiority_desc>
            <param_type>Ratios of GMTs</param_type>
            <param_value>4.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
            <estimate_desc>Ratio of GMTs at Day 43</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>3.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.37</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>6.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.54</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.23</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</title>
        <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after first vaccination.</description>
        <time_frame>Day 1 to 7</time_frame>
        <population>The analysis was done on the safety set which included the five subjects who received wrong vaccination according to the randomization. These five subjects were excluded from PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</title>
          <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after first vaccination.</description>
          <population>The analysis was done on the safety set which included the five subjects who received wrong vaccination according to the randomization. These five subjects were excluded from PPS.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persist crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever≥38.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</title>
        <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after second vaccination.</description>
        <time_frame>Day 22 to 28</time_frame>
        <population>The analysis was done on the safety set. Almost all the subjects across the vaccine groups received their first and second vaccinations within the protocol-specified window. While all the enrolled subjects received their first vaccination, 3% to 7% of subjects across the vaccine groups did not receive their second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</title>
          <description>Safety was measured in terms of the number of participants reporting solicited local and systemic reactions after second vaccination.</description>
          <population>The analysis was done on the safety set. Almost all the subjects across the vaccine groups received their first and second vaccinations within the protocol-specified window. While all the enrolled subjects received their first vaccination, 3% to 7% of subjects across the vaccine groups did not receive their second vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persist crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever≥38.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
        <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
        <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
        <population>The analysis was done on the subgroup of the per-protocol set(PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- No Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59-No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - No Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59-Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59-Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50) MF59-Previous Vaccinaiton</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59-Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
          <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
          <population>The analysis was done on the subgroup of the per-protocol set(PPS).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="62" upper_limit="82"/>
                    <measurement group_id="O2" value="37" lower_limit="27" upper_limit="49"/>
                    <measurement group_id="O3" value="78" lower_limit="68" upper_limit="86"/>
                    <measurement group_id="O4" value="44" lower_limit="33" upper_limit="55"/>
                    <measurement group_id="O5" value="75" lower_limit="60" upper_limit="86"/>
                    <measurement group_id="O6" value="22" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O7" value="85" lower_limit="69" upper_limit="95"/>
                    <measurement group_id="O8" value="45" lower_limit="29" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="66" lower_limit="55" upper_limit="76"/>
                    <measurement group_id="O3" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O4" value="78" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O5" value="96" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O6" value="71" lower_limit="54" upper_limit="84"/>
                    <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O8" value="73" lower_limit="56" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="O2" value="12" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="O3" value="16" lower_limit="9" upper_limit="25"/>
                    <measurement group_id="O4" value="21" lower_limit="13" upper_limit="31"/>
                    <measurement group_id="O5" value="8" lower_limit="2" upper_limit="20"/>
                    <measurement group_id="O6" value="2" lower_limit="0.062" upper_limit="13"/>
                    <measurement group_id="O7" value="12" lower_limit="3" upper_limit="27"/>
                    <measurement group_id="O8" value="15" lower_limit="6" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O2" value="42" lower_limit="31" upper_limit="54"/>
                    <measurement group_id="O3" value="84" lower_limit="75" upper_limit="91"/>
                    <measurement group_id="O4" value="49" lower_limit="39" upper_limit="60"/>
                    <measurement group_id="O5" value="81" lower_limit="67" upper_limit="91"/>
                    <measurement group_id="O6" value="27" lower_limit="14" upper_limit="43"/>
                    <measurement group_id="O7" value="91" lower_limit="76" upper_limit="98"/>
                    <measurement group_id="O8" value="50" lower_limit="34" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="56" upper_limit="77"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="83" lower_limit="74" upper_limit="90"/>
                    <measurement group_id="O5" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O6" value="76" lower_limit="60" upper_limit="88"/>
                    <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O8" value="78" lower_limit="62" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
        <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
        <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
        <population>The analysis was done on the subgroup on the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- No Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - No Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59-Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59-Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50) MF59-Previous Vaccinaiton</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59-with Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
          <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
          <population>The analysis was done on the subgroup on the per-protocol set (PPS).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.66" upper_limit="16"/>
                    <measurement group_id="O2" value="7.95" lower_limit="5.58" upper_limit="11"/>
                    <measurement group_id="O3" value="9.94" lower_limit="6.93" upper_limit="14"/>
                    <measurement group_id="O4" value="12" lower_limit="8.3" upper_limit="17"/>
                    <measurement group_id="O5" value="10" lower_limit="6.84" upper_limit="15"/>
                    <measurement group_id="O6" value="6.52" lower_limit="4.28" upper_limit="9.94"/>
                    <measurement group_id="O7" value="8.30" lower_limit="5.75" upper_limit="13"/>
                    <measurement group_id="O8" value="10" lower_limit="6.58" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="61" upper_limit="167"/>
                    <measurement group_id="O2" value="25" lower_limit="15" upper_limit="41"/>
                    <measurement group_id="O3" value="105" lower_limit="63" upper_limit="173"/>
                    <measurement group_id="O4" value="42" lower_limit="26" upper_limit="68"/>
                    <measurement group_id="O5" value="80" lower_limit="43" upper_limit="148"/>
                    <measurement group_id="O6" value="17" lower_limit="8.88" upper_limit="34"/>
                    <measurement group_id="O7" value="100" lower_limit="51" upper_limit="194"/>
                    <measurement group_id="O8" value="45" lower_limit="23" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975" lower_limit="663" upper_limit="1432"/>
                    <measurement group_id="O2" value="103" lower_limit="71" upper_limit="149"/>
                    <measurement group_id="O3" value="788" lower_limit="538" upper_limit="1154"/>
                    <measurement group_id="O4" value="186" lower_limit="129" upper_limit="271"/>
                    <measurement group_id="O5" value="389" lower_limit="226" upper_limit="669"/>
                    <measurement group_id="O6" value="57" lower_limit="32" upper_limit="103"/>
                    <measurement group_id="O7" value="483" lower_limit="269" upper_limit="867"/>
                    <measurement group_id="O8" value="124" lower_limit="69" upper_limit="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response Based on Baseline Seropositivity</title>
        <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10</description>
        <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- Baseline HI &lt;1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - HI &lt;1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59 - Baseline HI ≥1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59 - Baseline HI ≥1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response Based on Baseline Seropositivity</title>
          <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10</description>
          <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="62" upper_limit="81"/>
                    <measurement group_id="O2" value="31" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O3" value="82" lower_limit="73" upper_limit="90"/>
                    <measurement group_id="O4" value="39" lower_limit="29" upper_limit="50"/>
                    <measurement group_id="O5" value="77" lower_limit="61" upper_limit="89"/>
                    <measurement group_id="O6" value="36" lower_limit="19" upper_limit="56"/>
                    <measurement group_id="O7" value="74" lower_limit="57" upper_limit="88"/>
                    <measurement group_id="O8" value="56" lower_limit="40" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="56" upper_limit="76"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="77" lower_limit="67" upper_limit="85"/>
                    <measurement group_id="O5" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O6" value="71" lower_limit="51" upper_limit="87"/>
                    <measurement group_id="O7" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O8" value="74" lower_limit="58" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O5" value="62" lower_limit="45" upper_limit="77"/>
                    <measurement group_id="O6" value="39" lower_limit="22" upper_limit="59"/>
                    <measurement group_id="O7" value="54" lower_limit="37" upper_limit="71"/>
                    <measurement group_id="O8" value="64" lower_limit="47" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="62" upper_limit="81"/>
                    <measurement group_id="O2" value="31" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O3" value="82" lower_limit="73" upper_limit="90"/>
                    <measurement group_id="O4" value="39" lower_limit="29" upper_limit="50"/>
                    <measurement group_id="O5" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O6" value="57" lower_limit="37" upper_limit="76"/>
                    <measurement group_id="O7" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O8" value="74" lower_limit="58" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="56" upper_limit="76"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="77" lower_limit="67" upper_limit="85"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O6" value="82" lower_limit="63" upper_limit="94"/>
                    <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O8" value="92" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
        <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10 Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline (Day 1 (pre-vaccination)) as compared to those who are seronegative (HI titer &lt; 1:10).</description>
        <time_frame>Day 22 (three weeks after first vaccination); day 43 (three weeks after second vaccination)</time_frame>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- Baseline HI &lt;1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - HI &lt;1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59 - Baseline HI ≥1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59 - Baseline HI ≥1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
          <description>Subgroup analysis based on Subjects with a pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10 Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline (Day 1 (pre-vaccination)) as compared to those who are seronegative (HI titer &lt; 1:10).</description>
          <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
          <units>Titres</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" lower_limit="4.98" upper_limit="5.14"/>
                    <measurement group_id="O2" value="5.07" lower_limit="4.99" upper_limit="5.15"/>
                    <measurement group_id="O3" value="5.01" lower_limit="4.93" upper_limit="5.09"/>
                    <measurement group_id="O4" value="5.06" lower_limit="4.98" upper_limit="5.14"/>
                    <measurement group_id="O5" value="53" lower_limit="34" upper_limit="83"/>
                    <measurement group_id="O6" value="35" lower_limit="21" upper_limit="58"/>
                    <measurement group_id="O7" value="47" lower_limit="29" upper_limit="76"/>
                    <measurement group_id="O8" value="69" lower_limit="44" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="29" upper_limit="61"/>
                    <measurement group_id="O2" value="15" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O3" value="60" lower_limit="42" upper_limit="88"/>
                    <measurement group_id="O4" value="17" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O5" value="266" lower_limit="137" upper_limit="517"/>
                    <measurement group_id="O6" value="67" lower_limit="31" upper_limit="145"/>
                    <measurement group_id="O7" value="313" lower_limit="154" upper_limit="639"/>
                    <measurement group_id="O8" value="248" lower_limit="126" upper_limit="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566" lower_limit="398" upper_limit="804"/>
                    <measurement group_id="O2" value="65" lower_limit="46" upper_limit="93"/>
                    <measurement group_id="O3" value="577" lower_limit="404" upper_limit="825"/>
                    <measurement group_id="O4" value="96" lower_limit="67" upper_limit="137"/>
                    <measurement group_id="O5" value="660" lower_limit="390" upper_limit="1117"/>
                    <measurement group_id="O6" value="167" lower_limit="90" upper_limit="308"/>
                    <measurement group_id="O7" value="811" lower_limit="462" upper_limit="1426"/>
                    <measurement group_id="O8" value="420" lower_limit="246" upper_limit="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Persistence by Geometric Mean Titers (GMT)</title>
        <description>Immunogenicity was assessed in terms of Geometric Mean Titers (GMT at 6 months (Day 202)and 12 months (Day 387) after second vaccination.</description>
        <time_frame>6 months (Day 202) and 12 months (Day 387) after second vaccination</time_frame>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Persistence by Geometric Mean Titers (GMT)</title>
          <description>Immunogenicity was assessed in terms of Geometric Mean Titers (GMT at 6 months (Day 202)and 12 months (Day 387) after second vaccination.</description>
          <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.94" upper_limit="14"/>
                    <measurement group_id="O2" value="7.27" lower_limit="5.5" upper_limit="9.6"/>
                    <measurement group_id="O3" value="9.29" lower_limit="7.06" upper_limit="12"/>
                    <measurement group_id="O4" value="11" lower_limit="8.2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT (Day 202, N=45, 38, 46, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="111" upper_limit="280"/>
                    <measurement group_id="O2" value="33" lower_limit="20" upper_limit="54"/>
                    <measurement group_id="O3" value="205" lower_limit="133" upper_limit="316"/>
                    <measurement group_id="O4" value="42" lower_limit="25" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT (Day 387, N= 46, 37, 38, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="52" upper_limit="162"/>
                    <measurement group_id="O2" value="15" lower_limit="8.24" upper_limit="28"/>
                    <measurement group_id="O3" value="85" lower_limit="48" upper_limit="151"/>
                    <measurement group_id="O4" value="25" lower_limit="13" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period. Five subjects received wrong vaccination according to the randomization and were excluded from PPS but were included in the safety set.</time_frame>
      <desc>Local, systemic, and other reactions were collected from Study days 1 to 7 and 22 to 28. SAEs, medically attended visits, new onset of chronic diseases and AEs that lead to subject’s withdrawal were collected from Day 1 (post-consent) through Day 387 (12 months following second vaccination).</desc>
      <group_list>
        <group group_id="E1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Genital abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Croup infections</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

